Roth Affirms Cytokinetics (CYTK) at 'Buy'; Astellas Collaboration Development is Encouraging
Tweet Send to a Friend
Roth Capital maintains Cytokinetics (Nasdaq: CYTK) at Buy with a $13 price target following news that the company and Astellas ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
